SML1892

Sigma-Aldrich

JPH203 hydrochloride

≥98% (HPLC)

Sinónimos:
KYT 0353 hydrochloride, KYT0353 hydrochloride, SCHEMBL17360639 hydrochloride, O-(5-Amino-2-phenylbenzoxazole-7-yl)methyl-3,5-dichloro-L-tyrosine hydrochloride, (S)-2-Amino-3-(4-((5-amino-2-phenylbenzo[d]oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid hydrochloride, JPH 203 hydrochloride, KYT-0353 hydrochloride, O-[(5-Amino-2-phenyl-7-benzoxazolyl)methyl]-3,5-dichloro-L-tyrosine dihydrochloride
Empirical Formula (Hill Notation):
C23H19Cl2N3O4 · xHCl
Peso molecular:
472.32 (free base basis)
MDL number:
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 15 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(O)[C@@H](N)CC1=CC(Cl)=C(OCC2=CC(N)=CC3=C2OC(C4=CC=CC=C4)=N3)C(Cl)=C1

Biochem/physiol Actions

JPH203 (KYT-0353) selectively inhibits L-type amino acid transporter LAT1-dependent L-leucine uptake and growth in HT-29 and human LAT1-expressing S2 murine renal proximal tubule cell cultures, but not human LAT2-expressing S2 cells (IC50/GI50 = 0.06/4.1, 0.14/16.4, and >10/>1000 μM, respectively). When administered via intravenous injection (6.3-25 mg/kg/d from d0 to d13), JPH203 effectively inhibits HT-29-derived tumor growth in mice in vivo.

RIDADR

NONH for all modes of transport

Michael F Wempe et al.
Drug metabolism and pharmacokinetics, 27(1), 155-161 (2011-09-15)
Many primary human tumors and tumor cell lines highly express human L-type amino acid transporter 1 (hLAT1); cancerous cells in vivo are strongly linked to LAT1 expression. Synthetic chemistry and in vitro screening efforts have afforded a variety of novel...
Koji Oda et al.
Cancer science, 101(1), 173-179 (2009-11-11)
Most tumor cell membranes overexpress L-type amino acid transporter 1, while normal cell membranes contain l-type amino acid transporter 2; both are Na(+)-independent amino acid transporters. Therefore, compounds that selectively inhibit L-type amino acid transporter 1 offer researchers with a...
Junko Toyoshima et al.
Journal of pharmaceutical sciences, 102(9), 3228-3238 (2013-05-29)
JPH203 has been developed as an anticancer drug that inhibits L-type amino acid transporter 1-mediated essential amino acid uptake into tumor cells. This study sought to elucidate which drug transporters may be involved in JPH203 hepatic elimination, and to estimate...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.